Results – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Thu, 24 Aug 2023 16:52:04 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 SLANG Worldwide Announces Second Quarter 2023 Financial Results https://mjshareholders.com/slang-worldwide-announces-second-quarter-2023-financial-results/ Thu, 24 Aug 2023 16:52:04 +0000 https://cannabisfn.com/?p=2973997

Ryan Allway

August 24th, 2023

News, Top News


Strongest adjusted margins1 to date of 54%, demonstrating an increase from adjusted gross margins of 43% in Q2 of 2022

Adjusted gross profit1 of $4.5 million in Q2 2023, compared with $4.3 million in Q2 2022, representing a 6.3% increase year-over-year

Continued strong sales growth in Vermont, with revenue increasing by $1.8 million and $3.87 million, for the three month and six-month periods respectively ending June 30, 2023

$11.23 million in cash and restricted cash at August 15, 2023

Toronto, Ontario–(Newsfile Corp. – August 24, 2023) – SLANG Worldwide Inc(CNSX: SLNG) (OTCQB: SLGWF) (“SLANG” or the “Company“), a leading global cannabis consumer packaged goods (CPG) company with a diversified portfolio of popular brands, today released financial results for the three and six months ended June 30, 2023. All figures in this press release are stated in Canadian dollars unless otherwise noted.

“In Q2 2023, SLANG achieved another significant milestone with our strongest adjusted gross margins to date, showcasing our dedication to driving financial results across all areas of the business. We also used the quarter to introduce a compelling range of new high-margin products, which will continue to position us as leaders in a rapidly evolving cannabis market,” commented John Moynan, Chief Executive Officer of SLANG. “Our capacity to reduce operating expenses, streamline our vertically integrated operations, and introduce new higher-margin revenue channels in our Core Markets continues to drive our margin expansion and enhance our bottom-line growth. With a strong operational infrastructure in place to advance new growth initiatives, we are strategically focused on constant innovation for our customers in order to deliver today’s most demanded cannabis brands to key cannabis markets nationwide.”

“SLANG maintained strong sales growth in Vermont, increasing revenue by $1.8 million and $3.87 million, for the respective three month and six-month periods ending June 30, 2023. Our wholesale sales in Vermont in Q2 2023 also grew by 380% from Q1, showing strong growth momentum quarter-over-quarter. Despite Colorado’s slower growth, we are still outperforming our competitors in the state, with O.pen maintaining its #1 ranking by the BDSA as the top-performing vape cartridge brand in the state throughout Q2. For the first six months of 2023, we increased sales of O.pen cartridges in Colorado by 16% to 415,082 units from the comparable period of 2022 as our portfolio of leading brands has continued to drive solid sales performance.”

Second Quarter 2023 Operational Highlights and Growth Drivers:

  • Reported continued strong growth in Vermont, with revenue increasing by $1.8 million and $3.87 million, for the three month and six-month periods respectively ending June 30, 2023.
  • SLANG increased wholesale sales in Vermont in Q2 2023 by 380% from the first quarter of 2023, showing strong quarter-over-quarter growth momentum.
  • In Colorado, O.pen maintained its #1 ranking by the BDSA as the top-performing vape cartridge brand in Colorado throughout Q2. For the first six months of 2023, we increased unit sales of O.pen cartridges by 16% from the comparable period of 2022.
  • In June, launched the new 2-gram disposable cartridge in Colorado, exceeding our initial sales goal by 241%, selling over 7,200 new 2-gram disposable cartridges in the first month alone, and producing over $570,000 in sales through August 21, 20232.
  • Post-quarter end, the Company launched its first line of fast-acting cannabis-infused gummies under its Alchemy Naturals all-natural THC gummy brand in Vermont.

Second Quarter 2023 Financial Summary:

  • Revenue from continuing operations for the three months ended June 30, 2023, was $8.44 million, compared with $9.87 million in the three months ended June 30, 2022. The year-over-year decline was primarily driven by a reduction of $1.63 million in our Distribution sales and $0.96 million in our Emerging Market sales, partially offset by a $1.05 million increase in Core Market sales driven by growth in Vermont. For the six months ended June 30, 2023, revenue from continuing operations increased 5.6% to $19.3 million from $18.2 million in the prior year six-month period.
  • Gross profit of $4.4 million (52% gross margin) in Q2 2023, compared with $4.5 million (43% gross margin) in Q2 2022. Adjusted gross profit1 was $4.5 million (54% adjusted gross margin) in Q2 2023, compared with $4.3 million (43% adjusted gross margin) in Q2 2022, representing a 6.3% increase year-over-year.
  • EBITDA1 of $(1.2) million in Q2 2023, compared with $(1.1) million in Q2 2022. The reduction in EBITDA is primarily attributable to a $0.28 million reduction in gross profit offset by a $0.21 million reduction in operating expenses, both of which exclude depreciation costs.
  • Adjusted EBITDA1 of $(0.76) million in Q2 2023, compared with $(0.70 million) in Q2 2022. The reduction in Adjusted EBITDA is primarily attributable to a $0.19 million increase in operating expenses (excluding depreciation expenses, expected credit losses and share based payments), offset by $0.13 million increase in adjusted gross profit, excluding depreciation costs.
  • $10.07 million in cash and restricted cash on June 30, 2023, compared to $11.67 million in cash and restricted cash on March 31, 2023. The Company received an additional $1.63 million in ERTC (Employee Retention Tax Credit) from the Internal Revenue Service post quarter-end. As of August 15, 2023, SLANG had $11.23 million in cash and restricted cash compared to $11.92 million on December 31, 2022.

Second Quarter 2023 Financial Review

The consolidated financial statements were prepared in accordance with IFRS. The following is a selected presentation of the Income Statement for the three and six months ended June 30, 2023.

(In thousands of Canadian dollars except per share data and percentages) For the three months ended For the six months ended
  30-Jun-23 30-Jun-22 30-Jun-23 30-Jun-22
Net Operating Revenue From Continuing Operations 8,436 9,868 19,259 18,242  
Cost of goods sold 3,900 5,601 9,041 10,336  
Gross Profit Before Fair Value Adjustment of Biological Assets 4,536 4,267 10,218 7,906  
Realized fair value amounts included in inventory sold (609 ) (580 ) (1,032 ) (1,094 )
Unrealized gain on changes in fair value of biological assets 419 806 876 1,336  
Gross Profit 4,346 4,493 10,062 8,148  
Gross Profit Margin 52%   46%   52%   45%  
Operating expenses 6,235 7,087 12,015 14,573  
Operating Loss (1,889 ) (2,594 ) (1,953 ) (6,425 )
Other items (Impairment, FV adjustment, FX, gains/losses, taxes, etc.) (1,647 ) (951 ) (3,912 ) (1,633 )
Total Comprehensive Loss (3,536 ) (3,545 ) (5,865 ) (8,058 )
Earnings Per Share From Continuing Operations          
Basic (0.01 ) (0.03 ) (0.03 ) (0.09 )
Diluted (0.01 ) (0.03 ) (0.03 ) (0.08 )
(In thousands of Canadian dollars) For the three months ended For the six months ended  
  30-Jun-23 30-Jun-22 30-Jun-23 30-Jun-22  
Net Operating Revenue From Continuing Operations 8,436 9,868 19,259 18,242  
Cost of Goods Sold 3,900 5,601 9,041 10,336  
Realized fair value amounts included in inventory sold (609 ) (580 ) (1,032 ) (1,094 )
Unrealized gain on fair value of biological assets 419 806 876 1,336  
Cost of Goods Sold 4,090 5,375 9,197 10,094  
Gross Profit 4,346 4,493 10,062 8,148  
Gross Profit Margin 52%   46%   52%   45%  
Gross Profit before FV adjustment 4,536 4,267 10,218 7,906  
Gross Profit Margin before FV adjustment 54%   43%   53%   43%  
(In thousands of Canadian dollars) For the three months ended For the six months ended  
  30-Jun-23 30-Jun-22 30-Jun-23 30-Jun-22  
Total Comprehensive Loss (3,536 ) (3,545 ) (5,865 ) (8,058 )
EBITDA (Non-IFRS) (1,168 ) (1,096 ) (490 ) (3,455 )
Adjusted EBITDA (Non-IFRS) (762 ) (704 ) (22 ) (2,348 )

See the Company’s management’s discussion and analysis for the three and six months ended June 30, 2023 (the “Q2 2023 MD&A“) for a detailed reconciliation of EBITDA and Adjusted EBITDA to Operating Income / (Loss). SLANG’s financial statements and the Q2 2023 MD&A are available on SEDAR+ at www.sedarplus.ca, and on the Company’s Investor Relations website at www.slangww.com.

Non-IFRS Measures

EBITDA, Adjusted EBITDA, adjusted gross profit and adjusted gross margin are non-IFRS financial measures that the Company uses to assess its operating performance. EBITDA is defined as net earnings (loss) before net finance costs, income tax expense (benefit) and depreciation and amortization expense. Management defines Adjusted EBITDA as EBITDA adjusted for other non-cash items such as the impact of unrealized fair values, share based compensation expense, impairments, one-time gains and losses, and one-time revenues and expenses. Management defines adjusted gross profit as gross profit before fair value adjustment of biological assets. This data is furnished to provide additional information and are non-IFRS measures and do not have any standardized meaning prescribed by IFRS. The Company uses these non-IFRS measures to provide shareholders and others with supplemental measures of its operating performance. The Company also believes that securities analysts, investors and other interested parties, frequently use these non-IFRS measures in the evaluation of companies, many of which present similar metrics when reporting their results. As other companies may calculate these non-IFRS measures differently than the Company, these metrics may not be comparable to similarly titled measures reported by other companies. We caution readers that Adjusted EBITDA should not be substituted for determining net loss as an indicator of operating results, or as a substitute for cash flows from operating and investing activities. During 2022, the Company updated its definition of Adjusted EBITDA to include the impact of fair value amounts included in inventory sold and unrealized gain on changes in fair value of biological assets.

Conference Call Details

Management plans to host an investor conference call today, August 24, at 10:00 am ET to discuss the results.

Timing: Thursday, August 24, 2023 at 10:00 am ET
Dial In: 1(888) 440-5983 (US toll-free) or 1(646) 960-0202 (international)
Conference ID: 6291438
Webcast: A live webcast can be accessed via the Company’s website at www.slangww.com or https://events.q4inc.com/attendee/459259871

About SLANG Worldwide

SLANG Worldwide Inc. is the industry leader in branded cannabis consumer packaged goods, with a diversified portfolio of five distinct brands and products distributed across the U.S. Operating in 13 legal cannabis markets nationwide, SLANG specializes in acquiring and developing market-proven regional brands, as well as launching innovative new brands to seize global market opportunities and match evolving consumer tastes. The Company has over a decade of experience operating in the nascent and highly regulated cannabis sector, and its partners enjoy the benefits of that experience, with access to the SLANG playbook for successful operations, sales and marketing. Its strong product pipeline from uniquely positioned and scalable brands like O.pen, Alchemy Naturals, Ceres, Firefly, and partnerships with brands like Greenhouse Seed Company have a proven track record of success with the brands consistently ranking among the top performers in the states where SLANG operates. Learn more at slangww.com.

Forward-Looking Statements

This news release contains statements that constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management of SLANG at this time, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that could cause actual results to differ materially from those expressed or implied in such statements. Investors are cautioned not to put undue reliance on forward-looking statements. Applicable risks and uncertainties include, but are not limited to regulatory risks, risks related to the COVID-19 global pandemic, changes in laws, resolutions and guidelines, market risks, concentration risks, operating history, competition, the risks associated with international and foreign operations and the other risks identified under the headings “Risk Factors” in SLANG’s annual information form dated April 27, 2022 and other disclosure documents available on SEDAR+ at www.sedarplus.ca. SLANG is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Financial Outlook

This news release contains a financial outlook within the meaning of applicable Canadian securities laws. The financial outlook has been prepared by management of the Company to provide an outlook for the Company’s sales in certain markets during the period of July and August 2023, as well as cash balances and may not be appropriate for any other purpose. The financial outlook has been prepared based on a number of assumptions including the assumptions discussed under the heading “Forward-Looking Statements”. The actual results of the Company’s operations for any period will likely vary from the amounts set forth in these projections and such variations may be material. The Company and its management believe that the financial outlook has been prepared on a reasonable basis. However, because this information is highly subjective and subject to numerous risks, including the risks discussed under the heading “Forward-Looking Statements”, it should not be relied on as necessarily indicative of future results.

Third Party Information

This press release includes market and industry data that has been obtained from third party sources, including industry publications. The Company believes that the industry data is accurate and that its estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, the Company has not independently verified any of the data from third party sources referred to in this press release or ascertained the underlying economic assumptions relied upon by such sources.

Reader Advisory

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Company Contact
Mikel Rutherford, CFO
833-752-6499

Media and Investor Inquiries
Investors@SLANGww.com

KCSA Strategic Communications
Phil Carlson
SLANG@kcsa.com

________________________
1 See “Non IFRS measures”.
Preliminary and unaudited financial results are subject to customary financial statement procedures by the Company and its auditors. Actual results could be affected by subsequent events or determinations. While the Company believes there is a reasonable basis for these preliminary financial results, the results involve known and unknown risks and uncertainties that may cause actual results to differ materially. These preliminary fiscal results represent forward-looking information. See “Forward-Looking Statements” and “Financial Outlook”.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Global Hemp Industry Leader Experiences Dramatic Year-Over-Year Growth https://mjshareholders.com/global-hemp-industry-leader-experiences-dramatic-year-over-year-growth/ Wed, 01 Feb 2023 16:01:39 +0000 https://www.cannabisfn.com/?p=2972557

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as “expects”, “will”, “anticipates”, and “estimates”; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief “snapshot” of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled “Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

]]>
POSaBIT Reports First Quarter 2022 Financial Results https://mjshareholders.com/posabit-reports-first-quarter-2022-financial-results/ Thu, 26 May 2022 17:47:59 +0000 https://www.cannabisfn.com/?p=2948999

Ryan Allway

May 26th, 2022

News, Top News


Revenue increased 79% to $6.4 Million

Exited First Quarter with Largest Monthly Transactional Sales Volume

Reiterates Full Year 2022 Revenue Guidance of $37 to $40 Million

TORONTO & SEATTLE, May 26, 2022–(BUSINESS WIRE)–POSaBIT Systems Corporation (CSE: PBIT, OTC: POSAF), the leading provider of payments infrastructure in the cannabis industry, today announced its financial results for the three months ended March 31, 2022.

“We continued to onboard new merchants during the first quarter, primarily higher volume stores that, when coupled with anticipated same-store growth from our existing store footprint, reinforces our optimism for another year of exponential growth in 2022,” said Ryan Hamlin, CEO and Co-founder of POSaBIT. “Transactional sales volume began accelerating again towards the end of the first quarter with March transactional volume representing the largest month in our corporate history and that trend continued into the second quarter. To further drive growth, we unified our sales, marketing and customer support teams under the leadership of our new CRO, Julie Solomon, an experienced and accomplished executive in the fintech space. We are thrilled to add an executive of Julie’s caliber who will help us grow sales with existing retailers, add new retailers and expand into new markets.”

Hamlin continued, “Based on our current visibility, we are reaffirming our full-year 2022 revenue guidance of between $37 and $40 million, which represents growth of more than 80% at the midpoint compared to 2021.”

Recent Operational Highlights

  • Onboarded 44 of the 100+ newly booked stores since the May 3, 2022 public Q&A call
  • Increased count of contracted stores by additional 20% since the May 3, 2022 public Q&A call
  • Increased same store sales of top 20 locations by volume by 11% (Q1 2022 vs. Q1 2021)
  • Completed largest processing day in company’s history and sixth consecutive year of 100% uptime on 4/20/2022
  • Expanded leadership team with the appointment of Julie Solomon to the role of Chief Revenue Officer

First Quarter 2022 Financial Highlights

  • Transactional sales for payment Services totaled $103 million, up 61% compared with $64.0 million in the first quarter of 2021
  • Total revenue was $6.4 million, up 79% compared with $3.5 million in the first quarter of 2021
  • Gross profit was $1.5 million, or 24% of revenue, up 70% on a dollar basis compared with $900,000, or 25.4% of revenue in the first quarter of 2021
  • Net loss was $(470,000), inclusive of a $1.6 million non-cash change in fair value of derivative liabilities, compared with a net loss of $(514,000), inclusive of a $(322,000) non-cash change in fair value of derivative liabilities in the first quarter of 2021.
  • Adjusted EBITDA was $(1) million, or (16%) of revenue, compared with $71,000, or 20.0% of revenue, in the first quarter of 2021

Warrants and Cash Update

As of March 31, 2022, the company had cash of approximately $3.2 million compared to approximately $4.4 million as of December 31, 2021.

Financial Results

in US Dollars Three months ended
March 31, 2022 March 31, 2021 % Change
Revenue 6,359,733 3,546,343 +79.3%
Cost of goods sold 4,832,766 2,646,627 +82.6%
Gross profit 1,526,967 899,716 +69.7%
Gross profit margin 24.0% 25.4% (140) bps
Operating costs 3,556,180 1,036,709 +243%
Operating loss (2,029,213) (136,993) (1,381.3%)
Other expenses (income) 1,559,459 (367,757) (524%)
Net loss (469,754) (514,082) +8.6%

The following table reconciles Adjusted EBITDA to net loss, as reported.

Three months ended
March 31, 2022 March 31, 2021 Dec. 31, 2021
Loss, as reported (469,754 ) (514,080 ) (2,269,951 )
Add back: depreciation and amortization 57,470 74,152 57,197
Add back: share-based compensation, as reported 659,919 56,458 290,740
Add back / (deduct): foreign exchange (gains) / losses 320,202 107,156 (83,274 )
Add back / (deduct): change in fair value of financial instrument, as reported 3,046 (2,151 ) (11,900 )
Add back / (deduct): change in expected credit loss, as reported (1,993 ) (8,636 ) (4,804 )
Add back: fair value of derivative instrument, as reported (1,637,649 ) 322,381 519,301
Add back/(Deduct): finance costs, as reported 21,546 34,186 21,634
Add back interest accretion, as reported 30,129 20,676 (1,047 )
Add back loss on disposal of discontinued operations, as reported
Add back loss on related party-loan, as reported 219,379
Add back: disposal of assets, as reported 1,301
Add back: one-time processor penalty, as reported 200,000
Add back/ (deduct): transaction costs, as reported 25,462 9,331 (3,759 )
Adjusted EBITDA (991,622 ) 100,774 (1,066,484 )

2022 Outlook

The Company reiterates the following guidance for the full year 2022.

FY 2022
Total Revenue $37.0 to $40.0 million
Transaction sales for card services $675 to $730 million
Gross Profit Dollars $9.0 to $10 million

Conference Call Information

Date: May 26, 2022
Time: 4:30 pm Eastern Time
Toll-Free: 888-506-0062
International: 973-528-0011
Entry Code: 852067
Live Webcast: https://www.webcaster4.com/Webcast/Page/2708/45639

Conference Call Replay Information:

The replay will be available approximately 1 hour after the completion of the live event.

Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 45639
Replay Webcast: https://www.webcaster4.com/Webcast/Page/2708/45639

Financial Reports

Full details of the financial and operating results are described in the company’s consolidated financial statements with accompanying notes. The consolidated financial statements and additional information about POSaBIT are available on the company’s website at www.posabit.com/investor-relations or on SEDAR at www.sedar.com.

Non-IFRS Measures

Adjusted EBITDA and Adjusted net loss are non-IFRS measures used by management that do not have any prescribed meaning by IFRS and that may not be comparable to similar measures presented by other companies. The Company defines Adjusted EBITDA as net income or loss generated for the period as reported, before interest, taxes, depreciation and amortization and is further adjusted to remove changes in fair values and expected credit losses, foreign exchange gains and/or losses, impairments. The Company defines Adjusted net loss as net loss generated for the period as reported adjusted to remove changes in the fair values of derivative liabilities. The Company believes these non-IFRS measures are useful metrics to evaluate its core operating performance and uses these measures to provide shareholders and others with supplemental measures of its operating performance. The Company also believes that securities analysts, investors and other interested parties, frequently use these non-IFRS measures in the evaluation of companies, many of which present similar metrics when reporting their results. We caution readers that Adjusted EBITDA should not be substituted for determining net loss as an indicator of operating results, or as a substitute for cash flows from operating and investing activities.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding our business strategy, product development, timing of product development, events and courses of action.

Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as “anticipate,” “objective,” “may,” “will,” “might,” “should,” “could,” “can,” “intend,” “expect,” “believe,” “estimate,” “predict,” “potential,” “plan,” “is designed to” or similar expressions suggesting future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements about: our expectations regarding our expenses, sales and operations; our future customer concentration; our anticipated cash needs and our estimates regarding our capital requirements and our need for additional financing; our ability to anticipate the future needs of our customers; our plans for future products and enhancements of existing products; our future growth strategy and growth rate; our future intellectual property; and our anticipated trends and challenges in the markets in which we operate. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which POSaBIT will operate in the future, including the demand for our products, anticipated costs and ability to achieve goals. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements.

Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to, business, economic and capital market conditions; the ability to manage our operating expenses, which may adversely affect our financial condition; our ability to remain competitive as other better financed competitors develop and release competitive products; regulatory uncertainties; market conditions and the demand and pricing for our products; our relationships with our customers, distributors and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers’ needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; our ability to maintain technological leadership; our ability to manage risks inherent in foreign operations; the impact of technology changes on our products and industry; our failure to develop new and innovative products; our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of intellectual property litigation that could materially and adversely affect our business; our ability to manage working capital; and our dependence on key personnel. POSaBIT is an early stage company with a short operating history; it may not achieve profitability; and it may not actually achieve its plans, projections, or expectations.

Important factors that could cause actual results to differ materially from POSaBIT’s expectations include consumer sentiment towards POSaBIT’s products and blockchain/cryptocurrency exchange technology generally, litigation, global economic climate, loss of key employees and consultants, additional funding requirements, changes in laws, technology failures, competition, and failure of counterparties to perform their contractual obligations.

Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this news release. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise resulting from the use of the information in this news release or for omissions from the information in this news release.

Financial Outlook

This press release contains a financial outlook within the meaning of applicable Canadian securities laws. The financial outlook has been prepared by management of the Company to provide an outlook for the Company’s forecasted revenue, transaction sales for card services and gross profit for the 12 months to be ended December 31, 2022 and may not be appropriate for any other purpose. The financial outlook has been prepared based on a number of assumptions including the assumptions discussed under the heading “Forward-Looking Statements” herein. The actual results of the Company’s operations for any period will likely vary from the amounts set forth in these projections and such variations may be material. The Company and its management believe that the financial outlook has been prepared on a reasonable basis. However, because this information is highly subjective and subject to numerous risks, including the risks discussed under the heading “Forward-Looking Statements” herein, it should not be relied on as necessarily indicative of future results.

ABOUT POSABIT

POSaBIT (CSE: PBIT) is a financial technology company that delivers unique and innovative, blockchain-enabled payment processing and point-of-sale systems for cash-only businesses. POSaBIT specializes in resolving pain points for complex, high-risk, emerging industries like cannabis with an all-in-one solution that is compliant, user-friendly and utilizes top-of-the-line hardware. POSaBIT’s unique solution provides a safer and transparent environment for merchants while creating a better overall experience for the consumer. For additional information, visit: www.posabit.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005640/en/

Contacts

Investor Relations:
[email protected]

Media Relations:
Oscar Dahl
855-767-2248
[email protected]

Management:
Ryan Hamlin
Co-founder and CEO of POSaBIT
855-767-2248
[email protected]

Hayden IR
James Carbonara
(646) 755-7412
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Stem Holdings Reports Fiscal First Quarter 2022 Financial Results https://mjshareholders.com/stem-holdings-reports-fiscal-first-quarter-2022-financial-results/ Wed, 23 Feb 2022 17:04:58 +0000 https://www.cannabisfn.com/?p=2938622

Ryan Allway

February 23rd, 2022

News, Top News


BOCA RATON, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE) — Stem Holdings, Inc. (OTCQX: STMH) (CSE: STEM) (the “Company” or “Stem”), a vertically integrated cannabis operator, today announced its financial results for the fiscal first quarter 2022 ended December 31, 2021. All amounts are expressed in U.S. dollars unless indicated otherwise and are prepared under International Financial Reporting Standards (“IFRS”).

Steve Hubbard, Interim CEO and CFO of Stem, commented, “Our financial results during our fiscal first quarter 2022 reflects a period of transition as we divested our e-commerce and delivery wholly owned subsidiary on December 15, 2021. The recent business decisions we have made with Driven Deliveries and other non-core assets puts us on a path to positive working capital. We have decided to focus the majority of our resources on cultivation facilities in Oregon and retail stores in Oregon and California where, in particular, we have significant room for growth in the cultivation operations as we have recently been producing at less than 50% capacity.”

Financial Results for the Fiscal First Quarter 2022:
Revenue for the fiscal first quarter 2022 totaled $4.9 million, a decrease of 21% as compared to $6.2 million for the same period the year prior. Net revenue after discounts and returns totaled $4.2 million, a decrease of 20.1% as compared to $5.3 million for the same period the year prior, a decrease in retail sales resulting from general market conditions.

During the fiscal first quarter 2022, the Company reported impairment expense of $800 thousand predominately related to the impairment of investments and a non-refundable deposit.

The Company had other income during the three months ended December 31, 2021, of $2.4 million compared to other expenses of $.3 million for the comparable period of 2020, the increase in other income was primarily related to the change in fair value of warrant liabilities. In the three months ended December 31, 2021, we had recognized a loss from discontinued operations of $1.745 million related to the divesture of Driven compared to a loss of $.144 million in the comparable period of the prior year.

On December 31, 2021, we had working capital of approximately $1.3 million, which included cash and cash equivalents of $3.3 million. We reported a net loss of approximately $4.2 million and our net cash used in operating expenses totaled $2.0 million, our cash used in investing activities was $0.1 million and cash flows used in financing activities totaled $0.1 million. Total liabilities as of December 31, 2021 were reduced to $14.2 million as compared to $23 million as of September 30, 2021.

About Stem Holdings, Inc.
Stem is a multi-state, vertically integrated, cannabis company that, through its subsidiaries and its investments, is engaged in the cultivation, processing, packaging, distribution and branding of cannabis, hemp and their derivatives, including oils, edibles, concentrates. Additionally, the Company purchases, improves, leases, operates, and invests in properties for use in the production, distribution and sales of cannabis and cannabis-infused products licensed under the laws of the states of Oregon, Nevada, California, Massachusetts, and New York. As of December 31, 2021, Stem had ownership interests in 24 state issued cannabis licenses including nine (9) licenses for cannabis cultivation, three (3) licenses for cannabis processing, two (2) licenses for cannabis wholesale distribution, three (3) licenses for hemp production and seven (7) cannabis dispensary licenses.

Forward-Looking Statements
This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the future business, operations, expected financial position as a result of the divestiture of Driven Deliveries, and phrases containing words such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects and the other risks involved in the mineral exploration and development industry. Forward-looking statements are subject to significant risks and uncertainties, and other factors that could cause actual results to differ materially from expected results. Readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by law.

Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
+1 212.896.1254
[email protected]

Media Contact:
Mauria Betts
Director of Branding and Public Relations
971.266.1908
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Evogene Reports First Quarter 2021 Financial Results https://mjshareholders.com/evogene-reports-first-quarter-2021-financial-results/ Thu, 27 May 2021 01:08:38 +0000 https://www.cannabisfn.com/?p=2920587

Ryan Allway

May 26th, 2021


REHOVOT, IsraelMay 26, 2021 /PRNewswire/ — Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announces today its financial results for the first quarter of 2021.

Mr. Ofer Haviv, Evogene’s President and CEO, stated, “A major corporate target for this year and the year following is value creation and its recognition by the capital markets, through Evogene’s subsidiaries. Two main paths to achieve this target in life-science based companies, such as our subsidiaries, are: product advancement and commercialization, and demonstration of their underlying technological advantage.

With respect to product advancement, in 2021-2022, all our subsidiaries have significant milestones for pipeline advancement, and some of them are even expected to reach first product launches. We believe that announcing the achievement of such milestones, as they are reached, will enable the capital markets to properly appreciate the value created by the subsidiaries and will also be reflected in Evogene’s value recognition.

With respect to demonstration of the advantage of the underlying technology, we believe that it can be recognized through the rapid progress of our subsidiaries’ discovery and development pipelines. Moreover, any strategic collaboration entered into by a subsidiary, such as between AgPlenus and Corteva, or equity investment in a subsidiary by a strategic partner, such as Corteva’s investment in Lavie Bio, is a vote of confidence in the unique advantages of our technology.

As previously disclosed, some of our subsidiaries are targeting to achieve additional strategic collaborations during 2021-2022. We expect that such collaborations will enable the capital markets to further recognize the unique technological value of our subsidiaries, thus reflecting on Evogene’s value, as well.

I am pleased to report that both Evogene and our subsidiaries have been progressing in accordance with their plans during the first quarter of 2021. Each of our subsidiaries has a very promising product pipeline, and their activities are aiming to advance the products towards commercialization.”

Q1 2021 main achievements

Biomica

  • Received additional positive pre-clinical results in its immuno-oncology program demonstrating efficacy of its live biotherapeutic product consortium BMC128 in combination with immune-checkpoint-inhibitors, this time in melanoma.

Canonic

  • Entered into agreements for the production and distribution in Israel of Canonic’s medical cannabis products with Tikun Olam-Cannbit Pharmaceuticals to enable the planned launch of Canonic’s first product in 2022.

Lavie Bio

  • Recently appointed Mr. Russ Putland as Vice President Commercial, bringing significant commercial experience to the Lavie Bio management team in preparation for its anticipated product launches starting 2022.

Evogene’s Ag-Seed division

  • Entered a collaboration agreement with a U.S. company, Plastomics, whereby Evogene’s insect control genes, demonstrating new modes of action, will be introduced into soybean, utilizing Plastomics’ disruptive new technology.

“We enthusiastically look forward to continuing our progress, achieving our defined targets, entering into new collaborations, and expanding the use of our technology into new fields of activity,” Mr. Haviv concluded.

Consolidated financial results for the first quarter ended as of March 31, 2021:

Cash position: Evogene maintains a strong financial position for its activities with approximately $70.1 million in consolidated cash, cash related accounts, bank deposits and marketable securities as of March 31, 2021. Approximately $11.8 million of Evogene’s consolidated cash is appropriated to its subsidiary, Lavie Bio.

During the first quarter of 2021, our consolidated net cash usage, excluding $27.1 million of net proceeds raised through an “At the Market Offering” (“ATM”) initiated in January 2021 and concluded during February 2021, was approximately $5.2 million, or $4.0 million, if excluding Lavie Bio. The Company has no bank debt.

In March 2021 we announced a new “ATM” and we had not sold any shares under this offering as of the end of the quarter.

Research and Development (“R&D”) expenses: R&D expenses, which are reported net of grants received, were approximately $4.3 million for the first quarter of 2021 (including a non-cash expense of $0.3 million for amortization of share-based compensation), in comparison to $4.6 million (including a non-cash expense of $0.9 million for amortization of share-based compensation) in the first quarter of 2020. In the first quarter of 2021 the actual R&D expenses slightly decreased, mainly due to a decrease in share-based compensation expenses.

Business Development (“BD”) expenses: BD expenses were approximately $0.6 million for the first quarter of 2021 (including a non-cash expense of $0.1 million for amortization of share-based compensation), in comparison to $1.0 million (including a non-cash expense of $0.7 million for amortization of share-based compensation) in the first quarter of 2020.

General and Administrative (“G&A”) expenses: G&A expenses for the first quarter of 2021 were $1.5 million (including a non-cash expense of $0.1 million for amortization of share-based compensation), in comparison to $1.3 million (including a non-cash expense of $0.3 million for amortization of share-based compensation) in the first quarter of 2020. The increase is mainly attributed to the increase of the costs of directors’ and officers’ insurance, partially offset by a decrease in non-cash expenses of amortization of share-based compensation.

Operating loss:  Operating loss for the first quarter of 2021 was $6.3 million, in comparison to $6.9 million for the first quarter of 2020. The decrease in operating loss during the first quarter is attributed to the increase in revenues from collaboration agreements compared to the first quarter of 2020 and due to the decrease in aforementioned amortization of share-based compensation expenses.

Loss: The loss for the first quarter of 2021 was $7.1 million in comparison to a loss of $7.2 million for the first quarter of 2020. The slight decrease in the loss for the first quarter is attributed to the reduction in operating loss, partially offset by an increase in financing expenses mainly attributed to exchange rate differences and revaluation of pre-funded warrants.

Conference Call & Webcast Details:

Date: May 26, 2021

Time: 9:00 am EST; 16:00 Israel time

Dial-in number: 1-888-281-1167 toll free from the United States, or +972-3-918-0609 internationally

Webcast: Available at www.evogene.com

Replay Information: A replay of the conference call will be available approximately two hours following the completion of the call.

To access the replay, please dial 1-888-326-9310 toll free from the United States, or +972-3-925-5904 internationally. The replay will be accessible through May 28, 2021, and an archive of the webcast will be available on the Company’s website.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN, TASE: EVGN), is a leading company in leveraging computational biology to design novel products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. For more information, please visit www.evogene.com

Forward Looking Statements

This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. For example, Evogene is using forward-looking statement in this press release when it discusses its expected paths to value creation, its and its’ subsidiaries expected trials, studies, product advancements, commercializations, launches, pipelines, milestones, potential collaborations and other plans for 2021 and 2022, the potential advantages of its technology and its anticipated entry into new fields of activity. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene’s reports filed with the applicable securities authority, as well as a result of the impacts of the COVID-19 pandemic. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the COVID-19 pandemic), Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Evogene Investor Contact

US Investor Relations:

Aviva Banczewski / Rivka Neufeld

Investor Relations and Public Relations Manager

E: [email protected]

T: +972-8-931-1900

Joseph Green
Edison Group
E: [email protected]
T: +1 646-653-7030

Laine Yonker

Edison Group

E: [email protected]

T: +1 646-653-7035

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands (except share and per share data)

As of March 31,

As of December 31,

2021

2020

Unaudited

Audited

CURRENT ASSETS:

Cash and cash equivalents

$             38,642

$                    46,229

Marketable securities

19,948

Short-term bank deposits 

11,500

2,000

Trade receivables 

219

222

Other receivables and prepaid expenses

2,584

3,372

72,893

51,823

LONG-TERM ASSETS:

Long-term deposits

10

9

Right-of-use-assets

1,882

1,872

Property, plant and equipment, net

2,084

2,072

Intangible assets, net

15,909

16,139

19,885

20,092

$             92,778

$                    71,915

CURRENT LIABILITIES:

Trade payables

$                  993

$                         863

Employees and payroll accruals

2,397

2,535

Operating lease liability

758

777

Liabilities in respect of government grants

144

72

Pre-funded warrants

4,144

Deferred revenues and other advances

26

47

Other payables

1,024

1,238

5,342

9,676

LONG-TERM LIABILITIES:

Operating lease liability

1,592

1,663

Liabilities in respect of government grants

3,740

3,694

5,332

5,357

SHAREHOLDERS’ EQUITY:

Ordinary shares of NIS 0.02 par value:

230

200

  Authorized − 150,000,000 ordinary shares; Issued and
  outstanding – 40,414,229 shares as of March 31, 2021
  and 35,600,088 shares as of December 31, 2020

Share premium and other capital reserve

257,184

225,121

Accumulated deficit

(185,878)

(179,276)

Equity attributable to equity holders of the Company

71,536

46,045

Non-controlling interests

10,568

10,837

Total equity

82,104

56,882

$             92,778

$                    71,915

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

U.S. dollars in thousands (except share and per share data)

Three months ended

March 31,

 Year ended
December 31,

2021

2020

2020

Unaudited

Audited

Revenues

$               333

$               75

$          1,040

Cost of revenues

271

39

574

Gross profit

62

36

466

Operating expenses:

Research and development, net

4,297

4,587

17,287

Business development

570

970

2,672

General and administrative

1,454

1,337

5,321

Total operating expenses

6,321

6,894

25,280

Operating loss

(6,259)

(6,858)

(24,814)

Financing income

52

137

1,591

Financing expenses

(905)

(487)

(2,951)

Financing expenses, net

(853)

(350)

(1,360)

Loss before taxes on income

(7,112)

(7,208)

(26,174)

Taxes on income

8

6

32

Loss

$         (7,120)

$         (7,214)

$      (26,206)

Attributable to:

Equity holders of the Company

(6,602)

(6,228)

(23,374)

Non-controlling interests

(518)

(986)

(2,832)

$         (7,120)

$         (7,214)

$      (26,206)

Basic and diluted loss per share

$           (0.17)

$           (0.24)

$          (0.83)

Weighted average number of shares used in
   computing basic and diluted loss per share

38,959,623

25,754,297

28,158,779

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

Three months ended

March 31,

 Year ended
December 31,

2021

2020

2020

Unaudited

Audited

Cash flows from operating activities:

Loss

$          (7,120)

$           (7,214)

$      (26,206)

Adjustments to reconcile loss to net cash used in operating
   activities:

Adjustments to the profit or loss items:

Depreciation

330

420

1,792

Amortization of intangible assets

230

233

935

Share-based compensation

531

1,934

4,097

Pre-funded warrants issuance expenses

211

Decrease in accrued bank interest

12

25

64

Net financing expense

886

376

967

Taxes on income

8

6

32

1,997

2,994

8,098

Changes in asset and liability items:

Decrease (increase) in trade receivables

3

11

(150)

Decrease (increase) in other receivables

719

(157)

(1,300)

Increase in long-term deposits

(1)

Increase (decrease) in trade payables

123

(274)

(29)

Increase (decrease) in employees and payroll accruals

(138)

(639)

456

Decrease in other payables

(255)

(212)

(87)

Decrease in deferred revenues and other advances

(21)

(41)

(339)

430

(1,312)

(1,449)

Cash received (paid) during the period for:

Interest received

69

112

294

Interest paid

(57)

(50)

(238)

Taxes paid

(8)

(6)

(13)

Net cash used in operating activities

(4,689)

(5,476)

$      (19,514)

Cash flows from investing activities:

Purchase of property, plant and equipment

(183)

(291)

(682)

Proceeds from sale of marketable securities

201

1,044

2,097

Purchase of marketable securities

(20,281)

Proceeds from (investments in) bank deposits, net

(9,500)

2,500

8,000

Net cash provided by (used in) investing activities

$        (29,763)

$              3,253

$           9,415

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

Three months ended

March 31,

 Year ended
December 31,

2021

2020

2020

Unaudited

Audited

Cash flows from financing activities:

Proceeds from issuance of ordinary shares, net of issuance
expenses

27,108

18,658

Proceeds from issuance of pre-funded warrants

1,989

Proceeds from advances for pre-funded warrants

9

Proceeds from exercise of options

445

59

Repayment of lease liability

(167)

(177)

(639)

Proceeds from government grants

123

175

320

Repayment of government grants

(20)

(22)

Net cash provided by (used in) financing activities

27,489

(2)

20,374

Exchange rate differences – cash and cash equivalent
balances

(624)

(512)

1,206

Increase (decrease) in cash and cash equivalents

(7,587)

(2,737)

11,481

Cash and cash equivalents, at the beginning of the period

46,229

34,748

34,748

Cash and cash equivalents, at the end of the period

$           38,642

$          32,011

$         46,229

Significant non-cash activities

Acquisition of property, plant and equipment

$                64

$                17

$                57

Increase (decrease) of right-of-use asset recognized
with corresponding lease liability

$              162

$                   –

$             (41)

Exercise of options

$                   –

$                   –

$                57

Ordinary shares issuance expenses

$                50

$                   –

$                  –

Logo – https://mma.prnewswire.com/media/890385/Evogene_Logo.jpg

SOURCE Evogene

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
TILT Holdings Reports Record First Quarter 2021 Financial Resuts https://mjshareholders.com/tilt-holdings-reports-record-first-quarter-2021-financial-resuts/ Thu, 27 May 2021 00:48:03 +0000 https://www.cannabisfn.com/?p=2920585

Ryan Allway

May 26th, 2021


Record Q1 Revenue of $46.8 Million up 15% YoY and 11% QoQ

Record Adjusted EBITDA of $6.2 Million up 28% YoY and 36% QoQ

Reiterates 2021 Guidance of Revenue Between $205 – $210 Million and Adjusted EBITDA Between $30 -$32 Million

PHOENIX, May 25, 2021 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) ( CSE: TILT ) ( OTCQX: TLLTF , a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, reported its financial and operating results for the three-months ended March 31, 2021. All financial information is provided in U.S. dollars unless otherwise indicated.

“Our first quarter results reflect another period of strong execution as we continue to build an integrated B2B cannabis company that partners with leading MSOs, LPs and cannabis brands,” said Gary Santo, President of TILT. “The results of that execution and our team’s hard work show up where it matters—in the numbers. We generated double-digit revenue growth and reduced cash operating costs on an absolute basis, all from the same asset base. We are more efficient operators today and we are just getting started. Over the coming quarters, we expect to benefit from our recently added cultivation capacity and secure additional brand partners as we expand our portfolio of products and services for our B2B partners and the industry at large.”

Q1 2021 Financial Summary (vs. Q1 2020, where applicable)

  • Revenue increased 15% to $46.8 million compared to $40.6 million driven by growth in both cannabis and inhalation and accessory revenue. Cannabis revenue increased 45% to $11.7 million and inhalation and accessory revenue increased 8% to $35.1 million.
  • Gross profit before fair value adjustments increased 7% to $13.5 million or 29% of revenue, compared to $12.6 million or 31% of revenue. Gross margins were impacted by timing of capacity expansions in Massachusetts.
  • Operating expenses less non-cash adjustments for stock compensation, depreciation/ amortization and one-time charges was $7.9 million, a 10% decrease from $8.8 million. As a percentage of revenue, operating expenses totaled 17% compared to 22%.
  • Adjusted EBITDA increased 28% to $6.2 million compared to $4.9 million. As a percentage of revenue, Adjusted EBITDA totaled 13.2% compared to 12%.
  • At March 31, 2021, cash and cash equivalents increased 21% to $9.0 million compared to $7.4 million at December 31, 2020.

Q1 2021 Operational Highlights

  • Generated record accessory orders during the quarter.
  • Generated record flower sales for March in Pennsylvania, where cultivation yields are up 16% over the last five months.
  • Launched three Her Highness NYC branded products in Massachusetts within 30 days of signing manufacturing and distribution contract.
  • Completed expansion of additional grow rooms in Massachusetts, which more than doubles cultivation capacity in the state to 56,500 ft .
  • Taunton, MA medical dispensary reported record monthly revenue in March.
  • Increased footprint in the northeast with completed acquisition of Standard Farms Ohio LLC, which brings a 9,600 ft processing and CO2 extraction facility.

Operational Highlights Subsequent to Quarter End

  • President Gary Santo to succeed Mark Scatterday as CEO of TILT Holdings, effective June 1, 2021. Mark Scatterday to continue on as Chairman of the Board.
  • Approved for adult-use license in Brockton, Massachusetts; state license still pending.
  • Announced partnership with Airo Brands, a multi-state CPG company focused on proprietary inhalation products to launch products in Pennsylvania.

Earnings Call and Webcast

The Company will host a webcast at 5:00 PM ET today to discuss financial and operational results for the reported quarter.

The live webcast may be accessed from the Events and Presentations menu in the Investor Relations section of the Company’s website at http://public.viavid.com/index.php?id=144960 or to access the conference call via telephone, please dial, 1-877-705-6003. Please register at least 10 minutes prior to the scheduled start to download and install any necessary audio software.

A replay of the webcast will be available in the Past Events section of the Company’s Investor Relations website approximately 2 hours after the live event and will be archived for 30 days.

About TILT

TILT helps cannabis businesses build brands. Through a portfolio of companies providing technology, hardware, cultivation and production, TILT services brands and cannabis retailers across 36 states in the U.S., as well as Canada, Israel, Mexico, South America and the European Union. TILT’s core businesses include Jupiter Research LLC , a wholly-owned subsidiary and leader in the vaporization segment focused on hardware design, research, development and manufacturing; and cannabis operations, Commonwealth Alternative Care, Inc. in Massachusetts, Standard Farms LLC in Pennsylvania and Standard Farms Ohio, LLC in Ohio. TILT is headquartered in Phoenix, Arizona. For more information, visit www.tiltholdings.com .

Forward-Looking Information

This news release contains forward-looking information based on current expectations. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward looking information may include, without limitation, expectations regarding 2021 revenue and Adjusted EBITDA guidance, anticipated benefits from recently added cultivation capacity, expectations with respect to securing additional brand partners, the opinions or beliefs of management, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of TILT, and includes statements about, among other things, future developments, the future operations, strengths and strategy of TILT. Generally, forward looking information can be identified by the use of forward looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These statements should not be read as guarantees of future performance or results. These statements are based upon certain material factors, assumptions and analyses that were applied in drawing a conclusion or making a forecast or projection, including TILT’s experience and perceptions of historical trends, the ability of TILT to maximize shareholder value, current conditions and expected future developments, as well as other factors that are believed to be reasonable in the circumstances.

Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. TILT assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

By its nature, forward-looking information is subject to risks and uncertainties, and there are a variety of material factors, many of which are beyond the control of TILT, and that may cause actual outcomes to differ materially from those discussed in the forward-looking statements.

For additional information regarding forward-looking statements and their related risks, please refer to the “Risk Factors and Uncertainties” section in the Management Discussion and Analysis of the Company for the quarter and year ended on December 31, 2020, which is available on the Company’s SEDAR profile at www.sedar.com .

Non-IFRS Financial and Performance Measures

In addition to providing financial measurements based on International Financial Reporting Standards (“IFRS”), the Company provides additional financial metrics that are not prepared in accordance with IFRS. Management uses non-IFRS financial measures, in addition to IFRS financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate the Company’s financial performance. These non-IFRS financial measures are EBITDA and Adjusted EBITDA. Management believes that these non-IFRS financial measures reflect the Company’s ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as they facilitate comparing financial results across accounting periods and to those of peer companies. Management also believes that these non-IFRS financial measures enable investors to evaluate the Company’s operating results and future prospects in the same manner as management. These non-IFRS financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company’s ongoing operating results.

As there are no standardized methods of calculating these non-IFRS measures, the Company’s methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others.

Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

EBITDA and Adjusted EBITDA

EBITDA and Adjusted EBITDA are financial measures that are not defined under IFRS. The Company uses these non-IFRS financial measures, and believes they enhance an investor’s understanding of the Company’s financial and operating performance from period to period, because they exclude certain material non-cash items and certain other adjustments management believes are not reflective of the Company’s ongoing operations and performance. The Company calculates EBITDA as net income (loss), plus (minus) income taxes (recovery), plus (minus) finance expense (income), plus depreciation and amortization expense. Adjusted EBITDA excludes certain one-time, non-cash or non-operating expenses, as determined by management, including stock compensation expense, business acquisition expense, debt issuance costs, severance, unrealized (gain) loss on changes in fair value of biological assets and fair value changes in biological assets included in inventory sold.

Reconciliations of Non-IFRS Financial and Performance Measures

Adjusted EBITDA is reconciled to Net Loss below as well as the section labelled “Reconciliation of Net Income (Loss) to Non-IFRS Measures” in the Management Discussion and Analysis of the Company for the three months ended on March 31, 2021, which is available on the Company’s SEDAR profile at www.sedar.com .

Selected Financial Results

Table 1: Income Statement:
(in US$ thousands, unaudited)

Three Months Ended
($ thousands) Mar 31,
2021
Dec 31,
2020
Mar 31,
2020
Revenue $ 46,780 $ 42,265 $ 40,625
Cost of Goods Sold 33,327 30,985 28,000
Gross Profit, Before FV Adj. 13,453 11,280 12,625
Gross Margin %, Before FV Adj. 29 % 27 % 31 %
Gain on FV of Bio. Assets 14,720 13,650 15,971
FV of Bio. Assets in Inventory Sold (13,400 ) (14,063 ) (6,073 )
Gross Profit, After FV Adj. 14,773 10,867 22,523
Gross Margin %, After FV Adj. 32 % 26 % 55 %
Total Operating Expenses 13,108 49,703 14,215
Income (Loss) from Continuing Operations 1,665 (38,836 ) 8,308
Total Other Income (Expense) (2,768 ) (15,841 ) (2,212 )
Income Tax (Expense) Recovery (477 ) 9,313 (2,308 )
Net Income (Loss) from Continuing Operations $ (1,579 ) $ (45,364 ) $ 3,788
Net (Loss) from discontinued operations, net of tax (46,783 ) (3,737 )
Net Income (Loss) $ (1,579 ) $ (92,147 ) $ 51
EBITDA, Non-IFRS 6,421 (49,612 ) 13,765
Adjusted EBITDA, Non-IFRS $ 6,195 $ 4,545 $ 4,855

Table 2: Reconciliation of Non-IFRS Measures:

(in US$ thousands, unaudited)

Three Months Ended
($ thousands) Mar 31, 2020 Dec 31, 2020 Mar 31, 2020
Net (Loss) from Continuing Operations $ (1,579 ) $ (45,364 ) $ 3,788
Add (Deduct) Impact of:
Interest (Income) (603 ) (1,595 ) (840 )
Finance Expense 2,597 1,847 2,846
Income Tax Expense (Recovery) 477 (9,313 ) 2,308
Depreciation and Amortization 5,529 4,813 5,663
Total Adjustments 8,000 (4,248 ) 9,977
EBITDA (Non-IFRS) $ 6,421 $ (49,612 ) $ 13,765
Add (Deduct) Impact of:
Stock Compensation Expense 882 817 617
Severance 104
(Gain) Loss on Sale of Assets 67 (32 )
Lease Restructuring Costs (14 ) 267
Deferred Rent Adjustment (548 )
Legal Settlement 2 275
Unrealized (Gain) Loss on Investment in Equity Security 705 23
Loss on Loan Receivable 16,416
One time bad debt expense 2,169
Derecognition and impairment loss 34,076
Unrealized (Gain) on Changes in FV of Bio. Assets (14,720 ) (13,650 ) (15,971 )
FV Changes in Bio. Assets Included in Inventory Sold 13,400 14,063 6,073
Total Adjustments (226 ) 54,157 (8,910 )
Adjusted EBITDA (Non-IFRS) $ 6,195 $ 4,545 $ 4,855


Table 3: Condensed Consolidated Statements of Cash Flow:

(in US$ thousands, unaudited)

Mar 31, 2021 Mar 31, 2020
Cash provided by (used in) operating activities – continuing operations $ 2,621 $ 6,344
Cash (used in) operating activities – discontinuing operations (2,095 )
Net cash provided by operating activities 2,621 4,249
Cash (used in) provided by investing activities – continuing operations (350 ) 1,393
Cash (used in) investing activities – discontinuing operations (327 )
Net cash (used in) provided by investing activities (350 ) 1,066
Cash (used in) financing activities – continuing operations (747 ) (776 )
Cash (used in) financing activities – discontinuing operations
Net cash (used in) financing activities (747 ) (776 )
Effect of foreign exchange on cash and cash equivalents 4 1,310
Net change in cash and cash equivalents 1,528 5,848
Cash and cash equivalents, beginning of year 7,427 2,580
Cash and cash equivalents, end of year $ 8,955 $ 8,428


Table 4: Condensed Consolidated Statements of Financial Position (Select Items)

(in US$ thousands, unaudited) :

($ thousands) Mar 31,
2021
Dec 31,
2020
Cash and Cash Equivalents $ 8,955 $ 7,427
Biological Assets 15,076 11,201
Inventory 52,460 52,634
Total Current Assets 98,326 101,889
Property, Plant & Equipment, Net 68,580 66,795
Total Assets 427,163 429,604
Total Current Liabilities 41,919 44,488
Total Long-Term Liabilities 102,747 102,069
Total Shareholders’ Equity 282,497 283,047
Working Capital 56,407 57,401

The CSE has neither approved nor disapproved the contents of this news release.

Investor Relations Contact:
Taylor Allison
[email protected]

Media Contact:
Casey Hansen
MATTIO Communications
[email protected]
925.708.9127

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>